FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lowy, Andrew M.
Baldwin, Graham S.
Funding for this research was provided by:
National Health and Medical Research Council (508908, 1020983)
National Institutes of Health (CA155620-01)
Sir Edward Dunlop Medical Research Foundation